Hester Biosciences Limited (HESTERBIO.BO)
INR 2469.0
(1.32%)
INR 2469.0
(1.32%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 350.87 Million | 235.96 Million | 87.12 Million | 580.53 Million | 367.72 Million | 467.08 Million |
| Net Income | 188.89 Million | 401.54 Million | 535.02 Million | 501.03 Million | 413.26 Million | 568.56 Million |
| Depreciation & Amortization | 171.74 Million | 206.95 Million | 165.81 Million | 133.14 Million | 132.3 Million | 117.55 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 36.25 Million | -208.38 Million | -387.8 Million | 15.47 Million | -137.46 Million | -122.56 Million |
| Other non-cash items | 235.3 Million | -164.15 Million | -225.91 Million | -69.11 Million | -40.38 Million | -96.46 Million |
| Investing Cash Flow | -245.48 Million | -769.99 Million | -1.16 Billion | -383.72 Million | -744.73 Million | -217.27 Million |
| Investments in PPE | -243.97 Million | -777.62 Million | -957.1 Million | -407.42 Million | -734.98 Million | -226.53 Million |
| Acquisitions | 550 Thousand | 250 Thousand | -208.15 Million | 420 Thousand | 9.81 Million | 1.13 Million |
| Investment purchases | -2.06 Million | - | -213.21 Million | 12.53 Million | -23.29 Million | -8.42 Million |
| Sales/Maturities of investments | - | 2.28 Million | - | 10.74 Million | 3.72 Million | 6.58 Million |
| Other Investing Activities | -226.54 Million | 5.1 Million | 212.58 Million | 10 Thousand | 10 Thousand | 9.95 Million |
| Financing Cash Flow | -111.04 Million | 417.58 Million | 1.11 Billion | -182.19 Million | 187.43 Million | 26.51 Million |
| Debt repayment | -299.99 Million | -171.37 Million | -180.44 Million | -118.44 Million | -281.69 Million | -189.66 Million |
| Dividends payments | -68.05 Million | -85.07 Million | -85.07 Million | -56.15 Million | -71.79 Million | -102.55 Million |
| Common Stock Repurchased | - | - | -8.03 Million | -170.42 Million | - | - |
| Common Stock Issuance | - | - | 3.98 Million | 19.64 Million | - | - |
| Other Financing Activities | 260 Million | 674.02 Million | 1.38 Billion | 143.18 Million | 540.91 Million | 318.73 Million |
| Accounts receivables | 5.29 Million | -248.75 Million | -91.6 Million | -96.56 Million | -254.72 Million | 70.7 Million |
| Accounts payables | -35.41 Million | 119.64 Million | -100.67 Million | 80.63 Million | 98.63 Million | 6.1 Million |
| Inventory | 92.29 Million | -94.28 Million | -131.6 Million | 17.46 Million | -131.82 Million | -103.63 Million |
| Other working capital | -25.92 Million | 15.01 Million | -63.93 Million | 13.94 Million | 150.45 Million | -95.73 Million |
| Cash at beginning of period | 148.17 Million | 247.5 Million | 212.69 Million | 235.31 Million | 406.47 Million | 123.27 Million |
| Cash at end of period | 153.04 Million | 131.56 Million | 247.5 Million | 212.69 Million | 235.31 Million | 406.47 Million |
| Capital Expenditure | -243.97 Million | -777.62 Million | -957.1 Million | -407.42 Million | -734.98 Million | -226.53 Million |
| Effect of forex changes on cash | 1.57 Million | 510 Thousand | -1.79 Million | -37.24 Million | 18.42 Million | 6.87 Million |
| Net cash flow / Change in cash | 4.87 Million | -115.94 Million | 34.81 Million | -22.62 Million | -171.16 Million | 283.19 Million |
| Free Cash Flow | 106.9 Million | -541.66 Million | -869.98 Million | 173.11 Million | -367.26 Million | 240.55 Million |
| Breakdown | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 188.89 Million | 39.84 Million | 40.86 Million | 58.69 Million | 401.54 Million | 45.31 Million |
| Depreciation & Amortization | 171.74 Million | 37.49 Million | 42.84 Million | 53.99 Million | 206.95 Million | 53.65 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 36.25 Million | - | - | - | -208.38 Million | - |
| Other non-cash items | 235.3 Million | -37.49 Million | -42.84 Million | -53.99 Million | -164.15 Million | -53.65 Million |
| Investing Cash Flow | -245.48 Million | - | - | - | -769.99 Million | - |
| Investments in PPE | -243.97 Million | - | - | - | -777.62 Million | - |
| Acquisitions | 550 Thousand | - | - | - | 250 Thousand | - |
| Investment purchases | -2.06 Million | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | 2.28 Million | - |
| Other Investing Activities | - | - | - | - | 5.1 Million | - |
| Financing Cash Flow | -111.04 Million | - | - | - | 417.58 Million | - |
| Debt repayment | -299.99 Million | - | - | - | -171.37 Million | - |
| Dividends payments | -68.05 Million | - | - | - | -85.07 Million | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 260 Million | - | - | - | 674.02 Million | - |
| Accounts receivables | 5.29 Million | - | - | - | -248.75 Million | - |
| Accounts payables | -35.41 Million | - | - | - | 119.64 Million | - |
| Inventory | 92.29 Million | - | - | - | -94.28 Million | - |
| Other working capital | -25.92 Million | - | - | - | 15.01 Million | - |
| Cash at beginning of period | 148.17 Million | 130.38 Million | 89.52 Million | 148.17 Million | 247.5 Million | 102.86 Million |
| Cash at end of period | 153.04 Million | 39.84 Million | 130.38 Million | 58.69 Million | 131.56 Million | 148.17 Million |
| Capital Expenditure | -243.97 Million | - | - | - | -777.62 Million | - |
| Effect of forex changes on cash | 1.57 Million | - | - | - | 510 Thousand | - |
| Net cash flow / Change in cash | 4.87 Million | -90.54 Million | 40.86 Million | -89.48 Million | -115.94 Million | 45.31 Million |
| Free Cash Flow | 106.9 Million | 39.84 Million | 40.86 Million | 58.69 Million | -541.66 Million | 45.31 Million |
BAYERCROP
000550
SILVERTUC
003040
VNO-PO
GMET